Halozyme Therapeutics, Inc. (HALO)
| Market Cap | 8.18B +23.3% |
| Revenue (ttm) | 1.51B +39.1% |
| Net Income | 348.84M -28.1% |
| EPS | 2.84 -24.4% |
| Shares Out | 118.61M |
| PE Ratio | 24.28 |
| Forward PE | 7.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,054,255 |
| Open | 69.34 |
| Previous Close | 68.55 |
| Day's Range | 68.27 - 69.81 |
| 52-Week Range | 51.06 - 82.22 |
| Beta | 0.87 |
| Analysts | Buy |
| Price Target | 83.90 (+21.61%) |
| Earnings Date | Aug 4, 2026 |
About HALO
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini... [Read more]
Financial Performance
In 2025, Halozyme Therapeutics's revenue was $1.40 billion, an increase of 37.55% compared to the previous year's $1.02 billion. Earnings were $316.89 million, a decrease of -28.64%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for HALO stock is "Buy." The 12-month stock price target is $83.9, which is an increase of 21.61% from the latest price.
News
LifeMD partners with Halozyme subsidiary for exclusive testosterone program
LifeMD (LFMD) announced a strategic co-marketing collaboration with Antares Pharma, a subsidiary of Halozyme (HALO), supporting a direct-to-patient self-pay program for Xyosted. Under the agreement, L...
20 growth stocks priced as value stocks
A broad screen of U.S. stocks yields a list of companies trading at low valuations to expected earnings, with high projected revenue growth rates through 2028. The list of 20 stocks includes eight fin...
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based ...
Halozyme price target lowered to $93 from $96 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Halozyme (HALO) to $93 from $96 and keeps an Overweight rating on the shares. Halozyme reported “solid” Q1 results, 2026-2028 guidance was…
Halozyme Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw 42% revenue and 43% royalty growth, driven by ENHANZE-enabled products and strong partner launches. Guidance for 2026–28 was reaffirmed, with new collaborations, a $1B buyback, and robust pipeline momentum supporting long-term growth.
Halozyme Therapeutics Earnings release: Q1 2026
Halozyme Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Halozyme Therapeutics Quarterly report: Q1 2026
Halozyme Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Halozyme Therapeutics Slides: Q1 2026
Halozyme Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
Announcing New $1 billion Share Repurchase Program Projecting to Buy Back at Least $400 million in 2026 Total Revenue Increased 42% YOY to $377 million Royalty Revenue Increased 43% YOY to $241 millio...
Halozyme announces global collaboration and license agreement with GSK
Halozyme Therapeutics (HALO) announced the company entered into a global collaboration and license agreement with GSK (GSK). Under the collaboration, GSK has licensed Halozyme’s ENHANZE drug delivery ...
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
Marks first ENHANZE ® agreement to include ADC targets Collaboration also includes option for additional future targets First clinical trial projected to initiate in 2026 SAN DIEGO, May 7, 2026 /PRNew...
Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis
Halozyme (HALO) and Oruka Therapeutics (ORKA) announced that Halozyme’s wholly-owned subsidiary, Halozyme Hypercon, has entered into a global exclusive collaboration and license agreement with Oruka. ...
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Na...
Halozyme Therapeutics Transcript: AGM 2026
The meeting approved all proposals, including director elections and auditor ratification. Strong financial performance and pipeline expansion were highlighted, with new agreements and acquisitions positioning for future growth. Shareholder Q&A addressed capital allocation and ongoing litigation.
Halozyme to Report First Quarter 2026 Financial and Operating Results
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its first quarter 2026 financial and operating results on Monday, May ...
Halozyme names Darren Snellgrove as CFO
Halozyme Therapeutics (HALO) announced the appointment of Darren Snellgrove as CFO, effective June 8. Snellgrove will be responsible for leading Halozyme’s financial operations and strategy, including...
Halozyme Appoints Darren Snellgrove as Chief Financial Officer
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of Darren Snellgrove as Chief Financial Officer, effe...
Halozyme price target raised to $95 from $90 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme (HALO) to $95 from $90 and keeps a Buy rating on the shares. A Q1 royalty reset is…
Halozyme price target raised to $96 from $94 at Morgan Stanley
Morgan Stanley yesterday raised the firm’s price target on Halozyme (HALO) to $96 from $94 and keeps an Overweight rating on the shares. The firm adjusted the target as part…
Halozyme enters global global collaboration and license agreement with Vertex
Halozyme (HALO) announced its wholly-owned subsidiary, Halozyme Hypercon, entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals (VRTX). Under the collaboratio...
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
SAN DIEGO, April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a g...
Halozyme Therapeutics Proxy statement: Proxy filing
Halozyme Therapeutics filed a proxy statement on March 23, 2026, providing details for shareholder voting and corporate governance matters.
Halozyme Therapeutics Proxy statement: Proxy filing
Halozyme Therapeutics filed a proxy statement on March 23, 2026, providing details for shareholder voting and corporate governance matters.
Halozyme names David Ramsay as Interim CFO
Halozyme (HALO) announced that David Ramsay has been appointed Interim CFO, effective March 23. Ramsay will oversee all financial operations while the company continues its active search for a permane...
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
SAN DIEGO, March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer ...